Local Treatment (Primary Tumor and Metastases) in Metastatic Prostate Cancer

Nicolas Benziane-Ouaritini; Alberto Bossi; Paul Sargos

doi:10.1016/j.euf.2024.10.006

Local Treatment (Primary Tumor and Metastases) in Metastatic Prostate Cancer

Eur Urol Focus. 2024 Jul;10(4):509-510. doi: 10.1016/j.euf.2024.10.006. Epub 2024 Oct 28.

Authors

Nicolas Benziane-Ouaritini¹, Alberto Bossi², Paul Sargos³

Affiliations

¹ Department of Radiotherapy, Centre Azuréen de Cancérologie, Mougins, France.. Electronic address: [email protected].
² Radiotherapy Department, Centre Charlebourg-La Défense-Amethyst Radiothérapie, La Garenne-Colombes, France.
³ Department of Radiotherapy, Bergonie Institute, Bordeaux, France; Radiotherapy Department, Centre Charlebourg-La Défense-Amethyst Radiothérapie, La Garenne-Colombes, France.

PMID: 39462742
DOI: 10.1016/j.euf.2024.10.006

Abstract

For patients with low-volume de novo metastatic hormone-sensitive prostate cancer, addition of an androgen receptor pathway inhibitor and prostate radiotherapy to the standard (SOC) improves survival in comparison to the next most effective strategy (SOC + ARPI). For the subgroup with prior definitive treatment of the primary tumor, long-term outcomes and genomic predictors of response to metastasis-directed therapy suggest that this might be a reasonable option in selected patients.

Publication types

Review

MeSH terms

Androgen Antagonists / therapeutic use
Androgen Receptor Antagonists / therapeutic use
Humans
Male
Neoplasm Metastasis*
Prostatic Neoplasms* / pathology
Prostatic Neoplasms* / therapy

Substances

Androgen Receptor Antagonists
Androgen Antagonists